However, recent studies reported EAI045 [7] and BLU-945 [8] as potent next-generation (fourth-generation) novel EGFR TKIs that mediate the resistance to third-generation inhibitors for EGFR mutant-driven NSCLC targeting T790M and C797S mutations. Here, EGFR is linked to non-small cell lung carcinoma.